FDA writes a device class for gene panels that gauge inherited cancer risk

The Food and Drug Administration has created a formal category in its device rules for the DNA sequencing systems used to assess a person's inherited risk of cancer. A final order published in the Federal Register on 6 October 2026 classifies the "high throughput DNA sequencing for hereditary cancer predisposition assessment test system" into Class II, with special controls, and codifies it at 21 CFR 866.6095 [s1]. The order is effective 6 October 2026, though the underlying classification was applicable from 29 September 2023 [s1].

The agency defines the new generic device type as a qualitative in vitro diagnostic system intended to analyse human DNA extracted from human specimens in order to detect germline mutations in a panel of targeted cancer-related genes [s1]. Germline mutations are those a person is born with and can pass on, as distinct from the mutations a tumour acquires. The device, the order states, is meant to aid hereditary cancer predisposition assessment by qualified health care professionals in accordance with professional guidelines [s1].

Two limits in that definition matter. The device is "not intended for screening, prenatal testing, or as a stand-alone diagnostic test," and it is for prescription use only [s1]. In other words, it is a tool to help a clinician evaluate inherited risk within established guidelines — not a standalone verdict, and not a general-population screen.

How the category came to exist

The order is the end of a process that began with one company's product. On 29 March 2021 the FDA received a De Novo classification request from Invitae Corporation for its Common Hereditary Cancers Panel [s1]. The De Novo route exists for genuinely novel devices that have no legally marketed predicate to measure against.

That route is needed because of how the law treats new devices. Any device not in commercial distribution before 28 May 1976 is, by operation of law, placed into Class III — the most tightly regulated tier, which normally requires premarket approval — regardless of the actual risk it poses [s1]. De Novo lets a sponsor ask the agency to assign a lower class when general controls, together with tailored special controls, can reasonably assure the device's safety and effectiveness [s1]. On 29 September 2023 the FDA granted Invitae's request and classified the device into Class II [s1]. The order published this week is the formal step of adding that device type to the Code of Federal Regulations, where it sits under product code QVU in the pathology specialty [s2].

Why a Class II category is consequential

Writing the type into the regulations does more than tidy the rulebook. Once a device type is classified into Class II, later products that are substantially equivalent to it no longer have to run the De Novo gauntlet or seek premarket approval; their makers can instead use the lighter 510(k) premarket notification process, clearing their device against the established type as a predicate [s1]. The FDA says the action will enhance patients' access to beneficial innovation, in part by reducing the regulatory burden of the automatic Class III assignment [s1].

The special controls are the safeguard that makes the lower class defensible. The order sets out detailed requirements that any such system must meet — among them documentation of the genes, variant types and target regions the test covers, and validation of its analytical performance and of the way it calls and interprets variants [s1]. Those controls, combined with the general controls that apply to all devices, are what the agency determined would provide a reasonable assurance of safety and effectiveness [s1].

What is settled, and what is not

The document is regulatory plumbing with real downstream effects. It settles that hereditary cancer sequencing panels of this kind now have a defined Class II home in the device rules, a product code, and a set of special controls that future entrants must satisfy [s1][s2]. It does not approve or endorse any particular test's clinical performance beyond the device that prompted the classification, and it does not change the order's own caution that these panels are decision aids used within professional guidelines rather than stand-alone diagnoses or population screens [s1]. For patients, the practical import is indirect but real: by turning a once-novel test into a predicate, the FDA has lowered the barrier for more such panels to reach the clinic.

Sources

• [s1] Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System — U.S. Food and Drug Administration (Federal Register), 6 October 2026.
• [s2] Device Classification: High Throughput DNA Sequencing For Hereditary Cancer Predisposition Assessment Test System (product code QVU, 21 CFR 866.6095) — U.S. Food and Drug Administration (openFDA device/classification API).